Gilead Sciences, Inc.
Combination therapy comprising an ACC inhibitor
Last updated:
Abstract:
The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
Status:
Grant
Type:
Utility
Filling date:
5 Oct 2018
Issue date:
20 Apr 2021